Compare Incyte Corporation (INCY) vs Cloudflare Inc (NET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Cloudflare Inc — how do they compare? Incyte Corporation trades at $117.95 (market cap $23.11B), while Cloudflare Inc trades at $274.2 (market cap $96.69B). The key difference: Cloudflare Inc is far larger — about 4.2× Incyte Corporation's market cap. Which is the better fit depends on your goals.
| INCY | NET | |
|---|---|---|
Market Cap | $23.11B | $96.69B |
Sector | Health | Technology |
52-Week High | $118.52 | $281.69 |
52-Week Low | $67.38 | $160.16 |
Enterprise Value | $19.13B | $96.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Cloudflare (NET) trades at $275.19, down 0.87% on the day, as the stock consolidates near recent highs. The company continues to demonstrate strong revenue growth with Q1 2026 earnings beating expectations, though it remains unprofitable with a -3.72% net margin. Technical indicators show a bullish trend with the stock trading above key support levels, while analyst sentiment remains positive with 72.5% recommending Buy. Recent product launches including Precursor behavioral defense highlight ongoing innovation in cybersecurity.
Outlook remains cautiously optimistic as Cloudflare leverages AI-driven cybersecurity demand, though profitability concerns and high valuations (P/S 41.75) present risks. The stock trades below consensus price target of $265.07, suggesting potential upside if execution continues. Key risks include intense competition and the company's ability to achieve sustainable profitability amid significant infrastructure investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →
